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Abstract
It has been demonstrated that genes in a cell do not act independently. They interact with one another to com-
plete certain biological processes or to implement certain molecular functions. How to incorporate biological path-
ways or functional groups into the model and identify survival associated gene pathways is still a challenging
problem. In this paper, we propose a novel iterative gradient based method for survival analysis with group Lp
penalized global AUC summary maximization. Unlike LASSO, Lp (p < 1) (with its special implementation entitled
adaptive LASSO) is asymptotic unbiased and has oracle properties [1]. We first extend Lp for individual gene identi-
fication to group Lp penalty for pathway selection, and then develop a novel iterative gradient algorithm for pena-
lized global AUC summary maximization (IGGAUCS). This method incorporates the genetic pathways into global
AUC summary maximization and identifies survival associated pathways instead of individual genes. The tuning
parameters are determined using 10-fold cross validation with training data only. The prediction performance is
evaluated using test data. We apply the proposed method to survival outcome analysis with gene expression pro-
file and identify multiple pathways simultaneously. Experimental results with simulation and gene expression data
demonstrate that the proposed procedures can be used for identifying important biological pathways that are
related to survival phenotype and for building a parsimonious model for predicting the survival times.
Background
Biologically complex diseases such as cancer are caused
by mutations in biological pathways or functional
groups instead of individual genes. Statistically, genes
sharing the same pathway have high correlations and
form functional groups or biological pathways. Many
databases about biological knowledge or pathway infor-
mation are available in the public domain after many
years of intensive biomedical research. Such databases
are often named metadata, which means data about
data. Examples of such databases include the gene
ontology (GO) databases (Gene Ontology Consortium,
2001), the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database [2], and several other pathways on the
internet (e.g., http://www.superarray.com; http://www.
biocarta.com). Most current methods, however, are
developed purely from computational points without
utilizing any prior biological knowledge or information.
Gene selections with survival outcome data in the
statistical literature are mainly within the penalized Cox
or additive risk regression framework [3-8]. The L1 and
Lp (p < 1) penalized Cox regressions can work for
simultaneous individual gene selection and survival pre-
diction and have been extensively studied in statistics
and bioinformatics literature [8-11]. The performance of
the survival model is evaluated by the global area under
the ROC curve summary (GAUCS) [12]. Unfortunately,
those methods are mainly for individual gene selections
and cannot be used to identify pathways directly. In
microarray analysis, several popular tools for pathway
analysis, including GENMAP, CHIPINFO, and GOMI-
NER, are used to identify pathways that are over-
expressed by differentially expressed genes. These gene
set enrichment analysis (GSEA)methods are very infor-
mative and are potentially useful for identifying path-
ways that related to disease status [13]. One drawback
with GSEA is that it considers each pathway separately
and the pathway information is not utilized in the mod-
eling stage. Wei and Li [14] proposed a boosting algo-
rithm incorporating related pathway information for
classification and regression. However, their method can
only be applied for binary phenotypes. Since most
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ciated with the activities of multiple pathways, new sta-
tistical methods are required to select multiple pathways
simultaneously with the time-to-event phenotypes.
A ROC curve provides complete information on the
set of all possible combinations of true-positive and
false-positive rates, but is also more generally useful as a
graphic characterization of the magnitude of separation
between the case and control distributions. AUC is
known to measure the probability that the marker value
(score) for a randomly selected case exceeds the marker
v a l u ef o rar a n d o m l ys e l e c t e d control and is directly
related to the Mann-Whitney U statistic [15,16]. In sur-
vival analysis, a survival time can be viewed as a time-
varying binary outcome. Given a fixed time t, the
instances for which ti = t are regarded as cases and sam-
ples with ti >t are controls. The global AUC summary
(GAUCS) is then defined as GAUCS = P (Mj >Mk|tj
<tk), which indicates that subject who died at an earlier
time has a larger score value, where M is a score func-
tion. Heagerty and Zheng [12] have shown that GAUCS
is a weighted average of the area under time-specific
ROC curves. Liu et al. [17] proposed a L1 penalized
quadratic support vector machine (SVM) method for
GAUCS maximization and individual gene selection
with survival outcomes and showed the method outper-
formed the Cox regression. However, that method is
only for gene selections and can not be directly used for
identifying pathways without additional criteria. Group
LASSO (L1) related penalized methods have been exten-
sively studied recently in logistic regression [18], multi-
ple kernel learning [19], and microarray analysis [20]
with binary phenotypes. The methods are designed for
selecting groups of variables and identifying important
covariate groups (pathways). However, LASSO is biased.
Lp (p ≤ 1) (with one specific implementation entitled
adaptive LASSO [1,21]) is asymptotic unbiased and has
oracle properties. Therefore, it is reasonable to extend
the Lp to group Lp for pathway identifications. In this
paper, we therefore extend Lp to group Lp penalty and
develop a novel iterative gradient based algorithm for
GAUCS maximization (IGGAUCS), which can effec-
tively integrate genomic data and biological pathway
information and identify disease associated pathways
with right censored survival data. In Section 2, we for-
mulate the GAUCS maximization and group Lp penalty
model and propose an efficient EM algorithm for survi-
val prediction. Its performance is compared with its
group lasso penalized Cox regression (implemented by
ourselves). We also propose an integrated algorithm
with GAUCS for microarray data analysis. The proposed
approach is demonstrated with simulation and gene
expression examples in Section 3. Concluding remarks
are discussed in Section 4.
Group Lp Penalized GAUCS Maximization
Consider we have a set of n independent observations
{, , } tiii i
n  x =1,w h e r eδi is the censoring indicator and
ti is the survival time (event time) if δi =1o r
censoring time if δi =0 ,a n dxi is the m-dimensional
input vector of the ith sample. We denote
Nt it t i
*
() ()= ≤ 1 and the corresponding increment
dN t N t N t iii
*** () () ( ) =− − . The time-dependent sensi-
tivity and specificity are defined by sensitivity (c, t):
Pr Pr (| ) (| ( ) )
* Mc tt Mc d N t ii i i >= = > = 1 and specifi-
city (c, t): (( | ) ( | ( ) )
* Pr Pr Mc tt Mc N t ii i i ≤> = ≤ = 0 .
Here sensitivity measures the expected fraction of
subjects with a marker greater than c among the sub-
population of individuals who die (cases) at time t,
while specificity measures the fraction of subjects
with a marker less than or equal to c among those
who survive (controls) beyond time t. With this defi-
nition, a subject can play the role of a control for an
early time, t <ti, but then play the role of case when
t = ti. Then, ROC curves are defined as ROCt(q)=
TPt{[FPt]
-1(q)} for q  [0, 1], and the area under the
R O Cc u r v ef o rt i m et is AUC t ROC q dq t () = ∫ ()
0
1
,
where TPt and FPt are the true and false positive rate
at time t respectively, and [FPt]
-1(q)=i n f c{c : FPt(c) ≤ q}.
ROC methods can be used to characterize the ability of a
marker to distinguish cases at time t from controls at time
t. However, in many applications there is no prior time t
identified and thus a global accuracy summary is defined
by averaging over t:
GAUCS AUC t g t S t dt
MM tt jk j k
=
=><
∫ 2( ) ( ) ( )
(| ) , Pr
(1)
which indicates the probability that the subject who
died (cases) at the early time has a larger value of the
marker, where S(t)a n dg ( t) are the survival and corre-
sponding density functions, respectively.
Assuming there are r clusters in the input covariates,
our primary aim is to identify a small number of clus-
ters associated with survival time ti. Mathematically, for
each input xi  R
m, we are given a decomposition of R
m
as a product of r clusters:
 
mm mr =× × 1 , so that each data point xi can
be decomposed into r cluster components, i.e. xi =
(xi1,...,xir), where each xil is in general a vector. We
define M(x)=w
T x to be the risk score function, where
ww w w =( , , , ) 12
+, ,+ 

r
T r ∈
mm 1 is the vector of
coefficients that has the same cluster decomposition as
xi.W ed e n o t eMi = M(xi) for simplicity. Our goal is to
encourage the sparsity of vector w at the level of clus-
ters; in particular, we want most of its multivariate com-
ponents wl to be zero. The natural way to achieve this is
to explore the combination of Lp (0 ≤ p ≤ 1) norm and
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Page 2 of 13L2 norm. Since w is defined by clusters, we define a
weighted group Lp norm
Ld pl
l
r
l
p =
= ∑
1
|| , w
where within every group, an L2 norm is used
(| | ( ) )
/ ww w ll
T
l =
12 and dl can be set to be 1 if all clus-
ters are equally important. Note that group Lp = L2 if
r =1a n ddl = 1, and group Lp = Lp when r = m and dl
= 1. We can define the optimization problem
max max ( | )
.. ,
GAUCS Pr M M t t
L
jk j k
p
=> <
< st 
(2)
where Mj = w
T xj. The ideal situation is that M(xj)>
M(xk )o rw
T (xj - xk)>0 ,∀ couple (xj, xk) with corre-
sponding times tj <tk (or j <k) and δj =1 .
Pr(Mj >Mk|tj <tk) can be estimated as
GAUCS Pr M M t t
Mj Mk k
n jk
j
k
n jk
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where 1a>b =1i fa >b,a n d0o t h e r w i s e .O b v i o u s l y ,
GAUCS is a measure to rank the patients’ survival time.
The perfect GAUCS = 1 indicates that the order of all
patients’ survival time are predicted correctly and
GAUCS = 0.5 indicates for a completely random choice.
One way to approximate step function 1MM jk > is
to use a sigmoid function () z
e z =
+ −
1
1
and let
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Equation (4) is nonconvex function and can only be
solved with the conjugate gradient method to find a
local minimum. Based on the property that the arith-
metic average is greater than the geometric average, we
have

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We can, therefore, maximize the following log likeli-
hood lower bound of equation (4).
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where l is a penalized parameter controlling model
complexity. Equation (5) is the maximum a posterior
(MAP) estimator of w with Laplace prior provided we
treat the sigmoid function as the pair-wise probability,
i.e. Pr(Mj >M k)=s(w
T (xj - xk)). When p =1 ,Ep is a
convex function. A global optimal solution is
guaranteed.
The IGGAUCS Algorithm
In order to find the w that maximizes Ep,w en e e dt o
find the first order derivative. Since group Lp with p ≤ 1
is not differentiable at |wl| = 0, differentiable approxi-
mations of group Lp i sr e q u i r e d .W ep r o p o s eal o c a l
quadratic approximation for group |wl|
p based on con-
vex duality and local variational methods [23,24]. Fan
and Li [25] proposed a similar approximation for single
variable. The adaptive LASSO approach proposed by
Zou and Li [21] is a LASSO (linear bound) approxima-
tion for Lp penalty. The drawback with that approach is
that LASSO itself is not differentiable at |wl|=0 .S i n c e
|wl|
p is concave when p < 1, we can have
fg
gf
ll
p
ll l
ll l l
l
l
()| |m i n {|| ( ) }
() m i n {| | (
||
ww w == −
=−



  
2
2 ) )},
(6)
where the function g(.) is the dual function of f(.) in
variational analysis. Geometrically, g(hl)r e p r e s e n t st h e
amounts of vertical shift applied to hl|wl|
2 to obtain a
quadratic upper bound with precision parameter hl,t h a t
touches f(wl). Taking the first order derivative for
  ll l f
2 − () , the minimum occurs at a solution of sta-
tionary equation when θl ≠ 0,
20
2
  


ll l l f
f l
l
|| ( )
()
||
, − ′ =⇒ =
′
and f′(θl)=p|θl|
p-1. Substituting into f(wl), we have
the variational bound:
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(| | | | ) ( )
{| | | | ( ) |
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w
l
p
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l
p
l
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q u a d r a t i cb o u n d ,w eh a v et h ef o l l o w i n gs m o o t hl o w e r
bound.
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In equation (8), the lower bound E(w, θ) is differenti-
able w.r.t both w and θ. We therefore propose a EM
algorithm to maximize E(w, θ)w . r . tw while keeping θ
fixed and maximize E(w, θ) w.r.t the variational para-
meter θ to tighten the variational bound while keeping
w fixed. Convergence to the local optimum is guaran-
teed. Since maximization w.r.t the variational parameters
0 =( | θ1|,|θ2|,..., |θr|), with w being fixed, can be solved
with the stationary equation
∂
∂ =
E
l
(, )
||
w 
 0 we have θl =
wl, for l = 1, 2,..., r.
Given r candidate pathways potentially associated with
the survival time, ml survival associated genes with the
expression of xl on each pathway l (l = 1, 2,..., r), and
letting w =( w1, w2,..., wr)
T b eav e c t o ro ft h ec o r r e -
sponding coefficients and g
E ()
(, ) w w w
w =
∂
∂
 ,w eh a v e
the following iterative gradient algorithm for E(w, θ)
maximization:
The IGGAUCS Algorithm
Given p, l,a n d =1 0
-6, initializing w
1
1
1
2
11 = (, ,,) ww w  r
T
randomly with nonzero wl lr
1 1 ,, , =  ,a n ds e tθ
1 =w
1.
Update w with θ fixed:
w
t+1 = w
t + a
td
t,w h e r et: the number of iterations
and a
t: the step size, d
t is updated with the conju-
gate gradient method:
d
t =g ( w
t)+u
td
t and u
t g t g tT g t
g tT g t =
− −
−−
[( ) ( ) ] ( )
() ()
ww w
ww
1
11 .
Update θ with w fixed:
θ
t+1 = w
t+1
Stop when |w
t+1 - w
t|< or maximal number of
iterations exceeded.
Choice of Parameters
There are two parameters p and l in this method,
which can be determined through 10-fold cross valida-
tion. One efficient way is to set p = 0.1, 0.2,..., and 1
respectively, and search for an optimal l for each p
using cross validation. The best (p, l) pair will be found
with the maximal test GAUCS value. Theoretically when
p =1 ,E(w, θ) is convex and we can find the global max-
imum easily, but the solution is biased and small values
of p would lead to better asymptotic unbiased solutions.
Our results with limited experiments show that optimal
p usually happens at a small p such as p = 0.1. For com-
parison purposes, we implement the popular Cox
regression with group LASSO (GL1Cox), since there is
no software available in the literature. Our implementa-
tion is based on group LASSO penalized partial log-like-
lihood maximization. The best l is searched from l 
[0.1, 25] for IGGAUCS and from l  [0.1, 40] for
GL1Cox method with the step size of 0.1, as the Lp pen-
alty goes to zero much quicker than L1. We suggest that
the larger step size such as 0.5 can be used for most
applications, since the test GAUCS does not change dra-
matically with a small change of l.
Computational Results
Simulation Data
We first perform simulation studies to evaluate how
well the IGGAUCS procedure performs when input data
has a block structure. We focus on whether the impor-
tant variable groups that are associated with survival
outcomes can be selected using the IGGAUCS proce-
dure and how well the model can be used for predicting
the survival time for future patients. In our simulation
studies, we simulate a data set with a sample size of 100
and 300 input variables with 100 groups (clusters). The
triple variables x1 - x3, x4 - x6, x7 - x9,..., x298 - x300
within each group are highly correlated with a common
correlation g and there are no correlations between
groups. We set g = 0.1 for weak correlation, g =0 . 5f o r
moderate, and g = 0.9 for strong correlation in each tri-
ple group and generate training and test data sets of
sample size 100 with each g respectively from a normal
distribution with the band correlation structure. We
assume that the first three groups(9 covariates) (x1 - x3,
x4 - x6, x7 - x9) are associated with survival and the 9
covariates are set to be w = [-2.9 2.1 2.4 1.6 -1.8 1.4 0.4
0.8 -0.5]
t. With this setting, 3 covariates in the first
group have the strongest association (largest covariate
values) with survival time and 3 covariates in group 3
have less association with survival time. The survival
time is generated with H =1 0 0e x p ( - w
T x + ε)a n dt h e
Weibull distribution, and the census time is generated
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this setting, we would expect about 25% - 35% censor-
ing. To compare the performance of IGGAUCS and
GL1Cox, we build the model based on training data set
and evaluate the model with the test data set. We repeat
this procedure 100 times and use the time-independent
GAUCS to assess the predictive performance.
We first compare the performance of IGGAUCS and
GL1Cox methods with the frequency of each of these
three groups being selected under two different correla-
tion structures based on 100 replications. The results
a r ei nT a b l e1 .T a b l e1s h o w st h a tI G G A U C Sw i t hp =
0.1 outperforms the GL1Cox in that IGGAUCS can
identify the true group structures more frequently under
different inner group correlation structures. Its perfor-
mance is much better than GL1Cox regression, when
the inner correlation in a group is high (g = 0.9) and the
variables within a group have weak association with sur-
vival time.
To compare more about the performance of
IGGAUCS and GL1Cox in parameter estimation, we
show the results for each parameter with different inner
correlation structures (0.1, 0.5, 0.9) in Figure 1. For each
parameter in Figure 1, the left bar represents the para-
meter estimated from GL1Cox, the middle bar is the
true value of the parameter, and the right bar indicates
parameter estimated from IGGAUCS. We observe that
both the GL1Cox and IGGAUCS methods estimated the
sign of the parameters correctly for the first two groups.
However both methods can only estimate the sign of w8
correctly in group 3 with smaller coefficients. Moreover,
ŵ estimated from IGGAUCS is much closer to the true
w than that from GL1Cox, especially when the covari-
ates are larger. This indicates that the Lp (p = 0.1) pen-
alty is less biased than the L1 penalty. The estimators of
IGGAUCS are larger than that of GL1Cox with weak,
moderate, and strong correlations. Finally, the test glo-
bal AUC summaries (GAUCSs) of IGGAUCS and
GL1Cox with 100 replications are shown in Table 2.
Table 2 shows that IGGAUCS performs better than
GL1Cox regression. This is reasonable, since our
method, unlike Cox regression which maximizes a par-
tial log likelihood, directly maximizes the penalized
GAUCS. One interesting result is that the test GAUCSs
become smaller as the inner group correlation coeffi-
cient g increases from 0.1 to 0.9. We also apply the gene
harvesting method proposed by Hastie et al. (2001) and
discussed by Segal (2006) [7,26] to the simulation data,
but don’t show the results in Table 2. The gene harvest
method uses the average gene expression in each group
(cluster) and ignore the variance among genes within
the group. The prediction performances are poor with
t e s tG A U C So f0 . 5 7±0 . 0 2a n d0 . 6 5±0 . 0 1 6r e s p e c -
tively, when the correlations among genes are weak (g =
0.1) and moderate (g = 0.5). Its performance is slightly
better with the test GAUCS of 0.75 ± 0.024, when g =
0.9, but this4 performance is still not as good as either
IGGAUCS or GL1Cox. One explantation is that the
group is more heterogeneous with weaker correlations
among variables, and the average does not provide a
meaningful summary. Moreover, we cannot identify the
survival association of individual variables using gene
harvesting.
Follicular Lymphoma (FL) Data
Follicular lymphoma is a common type of Non-Hodgkin
Lymphoma (NHL). It is a slow growing lymphoma that
arises from B-cells, a type of white blood cell. It is also
called an “indolent” or “low-grad” lymphoma for its
slow nature, both in terms of its behavior and how it
looks under the microscope. A study was conducted to
predict the survival probability of patients with gene
expression profiles of tumors at diagnosis [27].
Fresh-frozen tumor biopsy specimens and clinical data
were obtained from 191 untreated patients who had
received a diagnosis of follicular lymphoma between
1974 and 2001. The median age of patients at diagnosis
was 51 years (range 23 - 81) and the median follow up
time was 6.6 years (range less than 1.0 - 28.2). The med-
ian follow up time among patients alive was 8.1 years.
Four records with missing survival information were
excluded from the analysis. Affymetrix U133A and
U133B microarray gene chips were used to measure
gene expression levels from RNA samples. A log 2
transformation was applied to the Affymetrix measure-
ment. Detailed experimental protocol can be found in
Dave et al. 2004. The data set was normalized for each
gene to have mean 0 and variance 1. Because the data is
very large and there are many genes with their expres-
sions that either do not change cross samples or change
randomly, we filter out the genes by defining a correla-
t i o nm e a s u r ew i t hG A U C Sf o re a c hg e n exi R(t, xi)=
|2GAUCS(t, xi)-1 | ,w h e r eR =1w h e nGAUCS =0 ,o r
1a n dR =0w h e nGAUCS =0 . 5( g e n exi is not
Table 1 Frequency of Three Survival Associated Groups
Selected in 100 Replications
IGGAUCS/GL1Cox
Parameters g = 0.1 g = 0.5 g = 0.9
w1 = -2.9
w2 = 2.1 100/100 100/100 100/100
w3 = 2.4
w4 = 1.6
w5 = -1.8 100/78 100/84 100/96
w6 = 1.4
w7 = 0.4
w8 = 0.8 47/2 53/4 94/24
w9 = -0.5
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Page 5 of 13associated with the survival time). We perform the per-
mutation test 1000 times for R to identify 2150 probes
associated with survival time. We then identify 49 candi-
date pathways with 5 and more genes using DAVID.
There are total 523 genes on the candidate pathways.
Since a gene can be involved in more than one pathway,
the number of distinguished genes should be a little less
than 500. The 49 biological pathways are given in Table
3. We finally apply IGGAUCS to identify the small
number of biological pathways associated with survival
phenotypes. We first randomly divide the data into two
subsets, one for training with 137 samples, and the
other for testing with 50 samples. To avoid overfitting
and bias from a particular partition, we randomly parti-
tion the data 50 times to estimate the performance of
the model with the average of the test GAUCS. The reg-
ularization parameter l is tuned using 10-fold cross-
validation with training data only.
Since it is possible different pathways may be selected
in the cross validation procedure, the relevance count
concept [28] was utilized to count how many times a
pathway is selected in the cross validation. Clearly, the
maximum relevance count for a pathway is 200 with the
10-fold cross validation and 20 repeating. We have
selected 8 survival associated pathways with IGGAUCS.
The average test GAUCS is 0.892 ± 0.013. Moreover,
the parameters (weights) wi and corresponding genes on
each pathway indicate the association strength and
−2
0
2
−2
0
2
w1 w2 w3 w4 w5 w6 w7 w8 w9
−2
0
2
GL1Cox True Values IGAUCS
r = 0.1
r = 0.5
r = 0.9
Figure 1 True and Estimated Parameters. The true and estimated parameters with the simulation data are shown in Figure 2. The left bars
represent each parameter estimated from GL1Cox, the middle bars are the true value of the parameter, and the right bars indicate parameters
estimated form IGGAUCS.
Table 2 Test GAUCS of Simulated Data with Different
Correlation Structures
Correlation IGGAUCS GL1Cox
g = 0.1 0.921(±0.023) 0.897(±0.031)
g = 0.5 0.889(±0.021) 0.871(±0.024)
g = 0.9 0.866(±0.017) 0.828(±0.025)
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Page 6 of 13direction between genes and the survival time. Positive
wis indicate that patients with high expression level die
earlier and negative wis represent that patients live
longer with relatively high expression levels. The abso-
lute values of |wi| indicate the strength of association
between survival time and the specific gene. Genes on
the pathway, estimated parameters, and relevance
accounts are given in Table 4.
The eight KEGG pathways identified play an impor-
tant role in patient survivals and they can be ranked
with the average |wj |:∑j |wj |/L,w h e r eL is the number
of genes on a pathway as shown in Table 5. The identi-
fied 8 KEGG pathways fall into three categories (i) sig-
naling molecules and interaction including the MAPK
signaling pathway, the Calcium signaling pathway, Focal
adhesion, ECM-receptor interactions and neuroactive
ligand-receptor interactions, (ii) metabolic pathways
including Fatty acid metabolism and Porphyrin and
chlorophyll metabolism, and (iii) nitric oxide and cell
stress including Ubiquitin mediated proteolysis. These
pathways are involved in different aspects of genetic
functions and are vital for cancer patient survivals. We
only discuss the MAPK signaling pathway but others
can be analyzed in a similar fashion. The top-rank
MAPK signaling pathway transduces a large variety of
external signals, leading to a wide range of cellular
responses, including growth, differentiation, inflamma-
tion, and apoptosis invasiveness and ability to induce
neovascularization. MAPK signaling pathway has been
linked to different cancers including follicular lymphoma
[29]. The pathway and genes on pathways are given in
Figure 2.
Genes in red color are highly expressed in patients
with aggressive FL and genes in yellow are highly
expressed in the earlier stage of FL cancers. Many
important cancer related genes are identified with our
methods. For example, SOS1, one of the RAS genes (e.
g., MIM 190020), encodes membrane-bound guanine
nucleotide-binding proteins that function in the trans-
duction of signals that control cell growth and differen-
tiation. Binding of GTP activates RAS proteins, and
subsequent hydrolysis of the bound GTP to GDP and
phosphate inactivates signaling by these proteins. GTP
binding can be catalyzed by guanine nucleotide
exchange factors for RAS, and GTP hydrolysis can be
accelerated by GTPase-activating proteins (GAPs). SOS1
plays a crucial role in the coupling of RTKs and also
intracellular tyrosine kinases to RAS activation. The
deregulation of receptor tyrosine kinases (RTKs) or
intracellular tyrosine kinases coupled to RAS activation
Table 3 Candidate Survival Associated Pathways
Pathways # of Genes Pathways # of Genes
Propanoate metabolism 5 Melanoma 10
Type II diabetes mellitus 6 Thyroid cancer 5
Adipocytokine signaling pathway 10 Prostate cancer 13
Melanogenesis 13 Glycolysis/Gluconeogenesis 8
GnRH signaling pathway 11 Butanoate metabolism 6
Insulin signaling pathway 15 Endometrial cancer 11
Sphingolipid metabolism 5 Pancreatic cancer 10
Glycerophospholipid metabolism 9 Colorectal cancer 12
T cell receptor signaling pathway 11 RNA polymerase 6
Hematopoietic cell lineage 10 Huntington’s disease 5
Glycerolipid metabolism 6 Focal adhesion 20
Toll-like receptor signaling pathway 13 Apoptosis 12
Antigen processing and presentation 9 Adherens junction 10
Complement and coagulation cascades 8 Tryptophan metabolism 7
ECM-receptor interaction 14 Histidine metabolism 6
Wnt signaling pathway 20 Fatty acid metabolism 10
Ubiquitin mediated proteolysis 15 Acute myeloid leukemia 9
Neuroactive ligand-receptor interaction 28 Bladder cancer 6
gamma-Hexachlorocyclohexane degradation 5 Focal adhesion 20
Calcium signaling pathway 21 ErbB signaling pathway 11
MAPK signaling pathway 31 PPAR signaling pathway 16
Valine, leucine and isoleucine degradation 6 Glioma 7
Pyrimidine metabolism 12 Chronic myeloid leukemia 10
Glycan structures - degradation 5 Non-small cell lung cancer 11
Porphyrin and chlorophyll metabolism 7
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wi GeneID Gene Name
ECM-receptor interaction (relevance counts: 200)
0.2239 CD36 cd36 antigen (collagen type i receptor, thrombospondin receptor)
0.0409 FNDC1 fibronectin type iii domain containing 1
0.0746 SV2C synaptic vesicle glycoprotein 2c
0.0804 SDC1 syndecan 1
-0.1255 FN1 fibronectin 1
0.0211 LAMC1 laminin, gamma 1 (formerly lamb2)
-0.0854 GP5 glycoprotein v (platelet)
-0.1130 CD47 cd47 antigen (rh-related antigen, integrin-associated signal transducer)
-0.1296 THBS2 thrombospondin 2
-0.0547 COL1A2 collagen, type i, alpha 2
-0.1024 COL5A2 collagen, type v, alpha 2
0.0861 LAMB4 laminin, beta 4
-0.0315 COL1A1 collagen, type i, alpha 1
0.0395 AGRN agrin RG
Focal adhesion (relevance counts 145)
0.0054 PAK3 p21 (cdkn1a)-activated kinase 3
0.0446 PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma)
0.0044 PDPK1 3-phosphoinositide dependent protein kinase-1
-0.0045 BAD bcl2-antagonist of cell death
0.0087 PARVA parvin, alpha
-0.0144 FN1 fibronectin 1
0.0041 LAMC1 laminin, gamma 1 (formerly lamb2)
-0.0202 PARVG parvin, gamma
-0.0158 THBS2 thrombospondin 2
0.0134 PPP1R12A protein phosphatase 1, regulatory (inhibitor) subunit 12a
-0.0044 SOS1 son of sevenless homolog 1 (drosophila)
-0.0084 COL1A2 collagen, type i, alpha 2
-0.0122 COL5A2 collagen, type v, alpha 2
0.0091 LAMB4 laminin, beta 4 RG Homo sapiens
-0.0068 RAF1 v-raf-1 murine leukemia viral oncogene homolog 1
-0.0038 ACTN1 actinin, alpha 1
-0.0034 COL1A1 collagen, type i, alpha 1
-0.0067 GSK3B glycogen synthase kinase 3 beta
-0.0065 MAPK8 mitogen-activated protein kinase 8
-0.0030 MYL7 myosin, light polypeptide 7, regulatory
Neuroactive ligand-receptor interaction (relevance counts: 200)
0.0894 P2RY6 pyrimidinergic receptor p2y, g-protein coupled, 6
-0.2753 PTAFR platelet-activating factor receptor
0.1648 GLRA3 glycine receptor, alpha 3
0.0857 FPRL1 formyl peptide receptor-like 1
-0.1783 EDNRA endothelin receptor type a
0.3233 HRH4 histamine receptor h4
0.2106 GRM2 glutamate receptor, metabotropic 2
-0.1112 GRIN1 glutamate receptor, ionotropic, n-methyl d-aspartate 1
-0.0220 PTHR1 parathyroid hormone receptor 1
0.0971 OPRM1 opioid receptor, mu 1
-0.4303 CTSG cathepsin g
-0.0404 P2RY8 purinergic receptor p2y, g-protein coupled, 8
-0.0783 BDKRB1 bradykinin receptor b1
0.3247 FSHR follicle stimulating hormone receptor
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-0.1430 ADRA1B adrenergic, alpha-1b-, receptor
0.1464 C3AR1 complement component 3a receptor 1
0.1120 P2RX2 purinergic receptor p2x, ligand-gated ion channel, 2
0.0311 AVPR1B arginine vasopressin receptor 1b
0.2646 FPR1 formyl peptide receptor 1
0.2003 GABRA5 gamma-aminobutyric acid (gaba) a receptor, alpha 5
-0.0278 PRLR prolactin receptor
-0.1070 ADORA1 adenosine a1 receptor
0.2652 HTR7 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled)
-0.0194 GABRA4 gamma-aminobutyric acid (gaba) a receptor, alpha 4
0.0145 GHRHR growth hormone releasing hormone receptor
-0.3163 MAS1 mas1 oncogene
-0.0760 PTGER3 prostaglandin e receptor 3 (subtype ep3)
0.2196 PARD3 par-3 partitioning defective 3 homolog (c. elegans)
Ubiquitin mediated proteolysis (relevance counts: 200)
0.0186 UBE2B ubiquitin-conjugating enzyme e2b (rad6 homolog)
-0.0677 CUL4A cullin 4a
0.0051 PML promyelocytic leukemia
-0.1023 UBE3B ubiquitin protein ligase e3b
-0.1581 UBE3C ubiquitin protein ligase e3c
0.1390 BTRC beta-transducin repeat containing
-0.0669 HERC3 hect domain and rld 3
0.00009 RBX1 ring-box 1
0.0011 CUL5 cullin 5
0.0267 ANAPC4 anaphase promoting complex subunit 4
-0.0253 UBE2L3 ubiquitin-conjugating enzyme e2l 3
0.0096 KEAP1 kelch-like ech-associated protein 1
-0.0267 UBE2E1 ubiquitin-conjugating enzyme e2e 1 (ubc4/5 homolog, yeast)
0.0116 CBL cas-br-m (murine) ecotropic retroviral transforming sequence
0.0328 BIRC6 baculoviral iap repeat-containing 6 (apollon)
Porphyrin and chlorophyll metabolism (relevance counts: 185)
0.0330 BLVRA biliverdin reductase a
-0.0103 FTH1 ferritin, heavy polypeptide 1
0.0227 ALAD aminolevulinate, delta-, dehydratase
0.1983 HMOX1 heme oxygenase (decycling) 1
0.0070 UROS uroporphyrinogen iii synthase (congenital erythropoietic porphyria)
-0.1596 GUSB glucuronidase, beta
0.0077 UGT2B15 udp glucuronosyltransferase 2 family, polypeptide b15
Calcium signaling pathway (relevance counts: 200)
-0.0025 BST1 bone marrow stromal cell antigen 1
0.0003 BDKRB1 bradykinin receptor b1
-0.0016 PTAFR platelet-activating factor receptor
-0.0002 ADRA1B adrenergic, alpha-1b-, receptor
-0.0007 PPP3CC protein phosphatase 3 (formerly 2b), catalytic subunit, gamma isoform
-0.0001 ADCY7 adenylate cyclase 7
0.0008 GNA11 guanine nucleotide binding protein (g protein), alpha 11 (gq class)
-0.0013 AVPR1B arginine vasopressin receptor 1b
0.0014 P2RX2 purinergic receptor p2x, ligand-gated ion channel, 2
-0.0013 CACNA1E calcium channel, voltage-dependent, alpha 1e subunit
0.0004 EDNRA endothelin receptor type a
0.00009 SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1
0.0006 CACNA1B calcium channel, voltage-dependent, l type, alpha 1b subunit
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-0.0013 PLCD1 phospholipase c, delta 1
-0.0029 HTR7 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled)
0.0014 GRIN1 glutamate receptor, ionotropic, n-methyl d-aspartate 1
0.0028 CAMK2A calcium/calmodulin-dependent protein kinase (cam kinase) ii alpha
-0.0024 CACNA1I calcium channel, voltage-dependent, alpha 1i subunit
-0.0002 TNNC1 troponin c type 1 (slow)
0.0009 PTGER3 prostaglandin e receptor 3 (subtype ep3)
0.0012 CACNA1F calcium channel, voltage-dependent, alpha 1f subunit
Fatty acid metabolism (relevance counts: 192)
0.0043 ACSL3 acyl-coa synthetase long-chain family member 3
0.0675 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial)
-0.0491 ACAT2 acetyl-coenzyme a acetyltransferase 2 (acetoacetyl coenzyme a thiolase)
0.0120 ALDH1B1 aldehyde dehydrogenase 1 family, member b1
0.0597 CYP4A11 cytochrome p450, family 4, subfamily a, polypeptide 11
-0.1447 ACADSB acyl-coenzyme a dehydrogenase, short/branched chain
0.0736 CPT1A carnitine palmitoyltransferase 1a (liver)
0.1075 CPT1B carnitine palmitoyltransferase 1b (muscle)
-0.0366 ACADVL acyl-coenzyme a dehydrogenase, very long chain
0.2168 ADH4 alcohol dehydrogenase 4 (class ii), pi polypeptide
MAPK signaling pathway (relevance counts: 200)
-0.1570 PLA2G10 phospholipase a2, group x
-0.2415 MAPKAPK5 mitogen-activated protein kinase-activated protein kinase 5
-0.1636 IL1B interleukin 1, beta
-0.0651 ZAK sterile alpha motif and leucine zipper containing kinase azk
0.0572 PPP3CC protein phosphatase 3 (formerly 2b), catalytic subunit, gamma isoform
-0.0674 MAP3K2 mitogen-activated protein kinase kinase kinase 2
-0.1729 JUND jun d proto-oncogene
-0.1718 SOS1 son of sevenless homolog 1 (drosophila)
0.1082 FGF14 fibroblast growth factor 14
0.3102 PTPN5 protein tyrosine phosphatase, non-receptor type 5
-0.3903 CACNB1 calcium channel, voltage-dependent, beta 1 subunit
0.2678 MAP3K7 mitogen-activated protein kinase kinase kinase 7
0.3176 CACNG8 calcium channel, voltage-dependent, gamma subunit 8
0.0893 FGF19 fibroblast growth factor 19
-0.0853 RRAS2 related ras viral (r-ras) oncogene homolog 2
0.0215 NLK nemo-like kinase
0.0452 MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4
0.1639 CACNA1E calcium channel, voltage-dependent, alpha 1e subunit
-0.0290 ARRB1 arrestin, beta 1
-0.1169 STK4 serine/threonine kinase 4
0.1008 CACNA1B calcium channel, voltage-dependent, l type, alpha 1b subunit
0.0839 MOS v-mos moloney murine sarcoma viral oncogene homolog
-0.1244 MEF2C mads box transcription enhancer factor 2, polypeptide c
0.1572 RAF1 v-raf-1 murine leukemia viral oncogene homolog 1
0.1757 MAPK8IP1 mitogen-activated protein kinase 8 interacting protein 1
0.2908 IKBKB inhibitor of kappa light polypeptide gene enhancer in b-cells, kinase beta
-0.3452 CACNA1I calcium channel, voltage-dependent, alpha 1i subunit
-0.2473 MAPK8 mitogen-activated protein kinase 8
-0.2339 CACNA1F calcium channel, voltage-dependent, alpha 1f subunit
0.0979 CD14 cd14 antigen
-0.1047 MRAS muscle ras oncogene homolog
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tumors, such as those in breast cancer, ovarian cancer
and leukemia. Another gene, IL1B, is one of a group of
related proteins made by leukocytes (white blood cells)
and other cells in the body. IL1B, one form of IL1, is
made mainly by one type of white blood cell, the macro-
phage, and helps another type of white blood cell, the
lymphocyte, fight infections. It also helps leukocytes
pass through blood vessel walls to sites of infection and
causes fever by affecting areas of the brain that control
body temperature. IL1B made in the laboratory is used
as a biological response modifier to boost the immune
system in cancer therapy.
As shown in Figure 2, the genes SOS1, IL1B, RAS,
C A C N B 1 ,M E F 2 C ,J U N D ,a n dM A P K A P K 5a r eh i g h l y
expressed in patients who were diagnosed earlier and
lived longer and the genes FGF14, PTPN5, MOS,
RAF1, CD14 are highly expressed in patients who were
diagnosed at more aggressive stages and died earlier,
which may indicate that oncogenes such such SOS1,
JUND, and RAS may initialize FL cancer and genes
such as MOS, IKK, and CD14 may cause FL cancer to
be more aggressive. There are several causal relations
among the identified genes on MAPK. For instance,
the down-expressed SOS and RAS cause the up-
expressed RAF1 and MOS and the up-stream gene IL1
Table 5 Pathway Ranks
Pathway ∑j |wj|/L Rank
MAPK signaling pathway 0.1614 1
Neuroactive ligand-receptor interaction 0.1562 2
ECM-receptor interaction 0.0863 3
Fatty acid metabolism 0.0772 4
Porphyrin and chlorophyll metabolism 0.0627 5
Ubiquitin mediated proteolysis 0.0494 6
Focal adhesion 0.0100 7
Calcium signaling pathway 0.0012 8
Figure 2 MAPK Signaling Pathway. MAPK signaling pathway and the associated genes. Genes in red are highly expressed in patients who
died earlier and genes in yellow are highly expressed in patients who lived longer.
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Page 11 of 13is coordinately expressed with CASP and the gene
MST1/2.
Conclusions
Since a large amount of biological information on var-
ious aspects of systems and pathways is available in pub-
lic databases, we are able to utilize this information in
modeling genomic data and identifying pathways and
genes and their interactions that might be related to
patient survival. In this study, we have developed a
novel iterative gradient algorithm for group Lp penalized
global AUC summary (IGGAUCS) maximization meth-
ods for gene and pathway identification, and for survival
prediction with right censored survival data and high
dimensional gene expression profile. We have demon-
strated the applications of the proposed method with
both simulation and the FL cancer data set. Empirical
studies have shown the proposed approach is able to
identify a small number of pathways with nice predic-
tion performance. Unlike traditional statistical models,
the proposed method naturally incorporates biological
pathways information and it is also different from the
commonly used Gene Set Enrichment Analysis (GSEA)
in that it simultaneously considers multiple pathways
associated with survival phenotypes.
With comprehensive knowledge of pathways and
mammalian biology, we can greatly reduce the hypoth-
esis space. By knowing the pathway and the genes that
belong to particular pathways, we can limit the number
of genes and gene-gene interactions that need to be
considered in modeling high dimensional microarray
data. The proposed method can efficiently handle thou-
sands of genes and hundreds of pathways as shown in
our analysis of the FL cancer data set.
There are several directions for our future investiga-
tions. For instance, we may want to further investigate
the sensitivity of the proposed methods to the misspeci-
fication of the pathway information and misspecification
of the model. We may also extend our method to incor-
porate gene-gene interactions and gene (pathway)-
environmental interactions.
Even though we have only applied our methods to
gene expression data, it is straightforward to extend our
methods to SNP, miRNA CGH, and other genomic data
without much modification.
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